CN103393724B - Ointment for treating perianal abscess and preparation method thereof - Google Patents
Ointment for treating perianal abscess and preparation method thereof Download PDFInfo
- Publication number
- CN103393724B CN103393724B CN201310348794.6A CN201310348794A CN103393724B CN 103393724 B CN103393724 B CN 103393724B CN 201310348794 A CN201310348794 A CN 201310348794A CN 103393724 B CN103393724 B CN 103393724B
- Authority
- CN
- China
- Prior art keywords
- group
- ointment
- present
- vaseline
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to an ointment for treating perianal abscess and a preparation method of the ointment. The ointment is a traditional Chinese medicine ointment prepared from muskone, calculus bovis factitius, pearl, calcined calamine, borax, borneol, chrysophoron, dimethylsulfoxide, vaseline, and lanum. The traditional Chinese medicine ointment has the efficacies of clearing away heat, drying dampness, invigorating the circulation of blood, removing swelling, removing the necrotic tissue and promoting granulation, is mainly applied to the hemorrhoid and anal fissure caused by dampness and hotness obstruction, specifically is applied to the symptoms of defecate haemorrhage, pain, and bearing down and is also applied to the symptoms of perianal eczema and the like. Compared with the prior art, the ointment is more reasonable in prescription, obviously improved in effect of clinical pharmacodynamics experiment, high in bioavailability and free from any toxic effect and side effect.
Description
Technical field
The present invention relates to and a kind ofly treat ointment of hemorrhoid class anorectal and preparation method thereof, belong to pharmaceutical technology sectors.
Technical background
Hemorrhoidal anus and rectum diseases belongs to clinical middle more common and multiple a kind of disease, and common is hemorrhoid, anal fissure, fecal blood or pain or have bearing down, anal eczema etc.Current doctor trained in Western medicine is mainly based on antibiosis anti-inflammatory drug treatment, and human body easily produces drug resistance; Serious also wants operative treatment, has a big risk, and Most patients is all difficult to accept.The traditional Chinese medical science has a lot of Chinese patent medicines in treatment hemorrhoidal anus and rectum diseases, but curative effect is not ideal enough mostly.Prior art patent retrieval: Chinese patent publication to disclose name and is called that " ointment for the treatment of hemorrhoid class anorectal and preparation method " publication number is the patent application of CN1403098A on March 19th, 2003; The weight proportion of the described ointment raw material of composition invention is: vaseline 700-900, Calculus Bovis 0.1-1, Margarita 0.1-1, Calamina 50-100, Borax 5-15, succinum 0.1-1, Borneolum Syntheticum 15-71, dimethyl sulfoxine 10-50, lanoline 20-60, Moschus 0.1-1.But we find that the effect of this ointment is desirable not enough in actual application.In the time in recent years, we are on the basis of prescription disclosed in this patent, carry out a large amount of tests to prescription consumption to grope, add the consumption of Calamina, and other consumptions are screened, have found best prescription proportioning, clinical pharrnacokinetics experiment effect significantly improves, we routinely technique made ointment.
Summary of the invention
The object of the invention is to: provide that a kind of curative effect is a kind of more significantly treats ointment of hemorrhoid class anorectal and preparation method thereof.The therapeutic effect that this ointment is used for hemorrhoidal anus and rectum diseases is better.
Ointment of the present invention, its formula is composed as follows:
Ointment of the present invention, its optimization formula is composed as follows:
The preparation method of ointment of the present invention is as follows:
A, Margarita, succinum to be pulverized, cross 100-120 mesh sieve;
B, by artificial Moschus, artificial Calculus Bovis, Borax, Borneolum Syntheticum, 1/5 Calamina (calcined and quenched) and steps A gained Margarita powder, Succinum powder facing-up, cross 100-120 mesh sieve;
C, step B gained medicated powder to be mixed homogeneously with 4/5 Calamina (calcined and quenched);
D, mixed medicated powder to be pulverized by drug powder metallization processes, obtain former powder;
E, by vaseline temperature control 80-100 DEG C fusing after, temperature control 115-120 DEG C sterilizing, is cooled to 70-80 DEG C by sterilized vaseline;
F, by lanoline in temperature control 115-120 DEG C sterilizing;
G, by dimethyl sulfoxine temperature control 55-65 DEG C to fusing;
H, first vaseline is put into material-compound tank, put into a half and stir; Secondly by Borneolum Syntheticum, dimethyl sulfoxine and lanoline congruent melting, filter and drop in material-compound tank and stir; 3rd is that former for step D gained powder is added material-compound tank, and stir, fill, obtains ointment.
Pharmacodynamic test of active extract proves: raw material weight proportioning of the present invention " artificial Moschus 0.78 part, artificial Calculus Bovis 0.78 part, Margarita 0.78 part, Calamina (calcined and quenched) 106.8 parts, Borax 6.8 parts, Borneolum Syntheticum 53.2 parts, succinum 0.78 part, dimethyl sulfoxine 19.4 parts, 762.1 parts, vaseline, lanoline 48.5 parts " with former invention weight proportion 1: 874.6 parts, vaseline, Calculus Bovis 0.12 part, Margarita 0.12 part, Calamina 62.5 parts, Borax 6.25 parts, succinum 0.12 part, Borneolum Syntheticum 18.7 parts, dimethyl sulfoxine 12.5 parts, lanoline 25 parts, 0.12 part, Moschus and former invention weight proportion 2: 750 parts, vaseline, Calculus Bovis 0.83 part, Margarita 0.83 part, Calamina 83.3 parts, Borax 12.5 parts, succinum 0.83 part, Borneolum Syntheticum 59.1 parts, dimethyl sulfoxine 41.7 parts, lanoline 50 parts, 0.83 part, Moschus and former invention weight proportion 3: 780 parts, vaseline, Calculus Bovis 0.8 part, Margarita 0.8 part, Calamina 80 parts, Borax 7 parts, succinum 0.8 part, Borneolum Syntheticum 54.8 parts, dimethyl sulfoxine 28 parts, lanoline 47 parts, 0.8 part, Moschus is compared, and results of pharmacodynamic test is significantly increased.
Pharmacodynamic test of active extract
One, the preparation of Experimental agents:
1, raw material:
A, ZHICHUANG GAO group of the present invention: prepared by artificial Moschus 0.8g, artificial Calculus Bovis 0.8g, Margarita 0.8g, Calamina (calcined and quenched) 110g, Borax 7g, Borneolum Syntheticum 54.8g, succinum 0.8g, dimethyl sulfoxine 20g, vaseline 785g, lanoline 50g.(by weight proportion of the present invention: artificial Moschus 0.78 part, artificial Calculus Bovis 0.78 part, Margarita 0.78 part, Calamina (calcined and quenched) 106.8 parts, Borax 6.8 parts, Borneolum Syntheticum 53.2 parts, succinum 0.78 part, dimethyl sulfoxine 19.4 parts, 762.1 parts, vaseline, lanoline 48.5 parts of proportionings)
B, former invention 1 group: prepared by vaseline 700, Calculus Bovis 0.1, Margarita 0.1, Calamina 50, Borax 5, succinum 0.1, Borneolum Syntheticum 15, dimethyl sulfoxine 10, lanoline 20, Moschus 0.1.(by former invention weight proportion 1: 874.6 parts, vaseline, Calculus Bovis 0.12 part, Margarita 0.12 part, Calamina 62.5 parts, Borax 6.25 parts, succinum 0.12 part, Borneolum Syntheticum 18.7 parts, dimethyl sulfoxine 12.5 parts, lanoline 25 parts, Moschus 0.12 part of proportioning)
C, former invention 2 groups: prepared by vaseline 900, Calculus Bovis 1, Margarita 1, Calamina 100, Borax 15, succinum 1, Borneolum Syntheticum 71, dimethyl sulfoxine 50, lanoline 60, Moschus 1.(by former invention weight proportion 2: 750 parts, vaseline, Calculus Bovis 0.83 part, Margarita 0.83 part, Calamina 83.3 parts, Borax 12.5 parts, succinum 0.83 part, Borneolum Syntheticum 59.1 parts, dimethyl sulfoxine 41.7 parts, lanoline 50 parts, Moschus 0.83 part of proportioning)
D, former invention 3 groups: prepared by vaseline 780, Calculus Bovis 0.8, Margarita 0.8, Calamina 80, Borax 7, succinum 0.8, Borneolum Syntheticum 54.8, dimethyl sulfoxine 28, lanoline 47, Moschus 0.8.(by former invention weight proportion 3: 780 parts, vaseline, Calculus Bovis 0.8 part, Margarita 0.8 part, Calamina 80 parts, Borax 7 parts, succinum 0.8 part, Borneolum Syntheticum 54.8 parts, dimethyl sulfoxine 28 parts, lanoline 47 parts, Moschus 0.8 part of proportioning)
2, the method for making of a, b, c, d is:
A, Margarita, succinum to be pulverized, cross 100-120 mesh sieve;
B, by artificial Moschus, artificial Calculus Bovis, Borax, Borneolum Syntheticum, 1/5 Calamina (calcined and quenched) and steps A gained Margarita powder, Succinum powder facing-up, cross 100-120 mesh sieve;
C, step B gained medicated powder to be mixed homogeneously with 4/5 Calamina (calcined and quenched);
D, mixed medicated powder to be pulverized by drug powder metallization processes, obtain former powder;
E, by vaseline temperature control 80-100 DEG C fusing after, temperature control 115-120 DEG C sterilizing, is cooled to 70-80 DEG C by sterilized vaseline;
F, by lanoline in temperature control 115-120 DEG C sterilizing;
G, by dimethyl sulfoxine temperature control 55-65 DEG C to fusing;
H, first vaseline is put into material-compound tank, put into a half and stir; Secondly by Borneolum Syntheticum, dimethyl sulfoxine and lanoline congruent melting, filter and drop in material-compound tank and stir; 3rd is that former for step D gained powder is added material-compound tank, and stir, fill, obtains ointment.
Two: process of the test and result of the test
Experiment purpose: by the pharmacological experiment study of the effect such as antiinflammatory, analgesia, blood coagulation, hemostasis to ZHICHUANG GAO of the present invention and b group, c group, d group, ZHICHUANG GAO of the present invention and b group, c group, d group are contrasted, observes the power of its pharmacological action.
Test method: ZHICHUANG GAO of the present invention and b group, c group, d group are on the impact of mice auricle swelling; The impact swollen on rat granuloma; On the impact of mouse peritoneal capillary permeability; The impact of Dichlorodiphenyl Acetate induced mice writhing response; On the impact of mouse hot-plate induced pain; On the impact of clotting time of mice; The mice bleeding time is affected.
One, on the impact of mice auricle swelling
Experiment material
1, animal: Kunming mouse, male and female have concurrently, body weight 18 ~ 22g.
2, medicine: ZHICHUANG GAO of the present invention and b group, c group, d group four dosage groups.
Experimental technique
Kunming mouse 50, male and female half and half, body weight 18 ~ 22g, is divided into 5 groups at random, often organizes 10.Matched group smears the vaseline of equivalent; ZHICHUANG GAO group of the present invention and b group, c group, d group smear the equal 2.4g/kg of administration respectively.Abdominal part depilation administration, successive administration 4d, every day 1 time.After last smears administration 0.5h, be only applied to the outer two sides of left in ear with 100% dimethylbenzene 0.2ml/, auris dextra is coated with normal saline and uses in contrast, cause scorching rear 1h, mice dislocation is put to death, beats round auricle with 9mm card punch, accurately weigh respectively, the difference of two auricle weight is as swelling.Experimental result: in table 1
Table 1 is on the impact of mice auricle swelling
* * P < 0.01 compared with matched group; With ZHICHUANG GAO of the present invention than △ P < 0.05.
Result shows: ZHICHUANG GAO group of the present invention and b group, c group, d group can significantly alleviate the swelling being caused Mice Auricle by dimethylbenzene, have pole significant difference (P < 0.01) compared with matched group; ZHICHUANG GAO of the present invention has significant difference (P < 0.05) compared with b group, c group, d group.Visible, ZHICHUANG GAO of the present invention is stronger than b group, c group, the effect of d group anti-inflammation.
Two, on the impact that rat granuloma is swollen
Experiment material
1, animal: SD kind rat, male and female have concurrently, body weight 180 ~ 220g.
2, medicine: ZHICHUANG GAO of the present invention and b group, c group, d group four dosage groups.
Experimental technique
SD kind rat 50, male and female half and half, body weight 180 ~ 220g, is divided into 5 groups at random, often organizes 10.During test, ether light anaesthesia, wipe out rat chesk hair, iodine disinfection, cut skin of chest, each one of the aseptic cotton balls of 20mg (soak with mycillin mixed liquor 0.2ml and dry after autoclaving) is filled in respectively, skin suture, intramuscular injection green grass or young crops, chain enzyme infection from otch to two forelimb oxters.Postoperative 1h smears administration, and matched group smears the vaseline of equivalent; ZHICHUANG GAO group of the present invention and b group, c group, d group smear the equal 1.6g/kg of administration respectively.Abdominal part depilation administration, successive administration 4d, every day 1 time, puts to death rat in 5d cervical dislocation, peels off cotton balls granulation tissue, after 70 DEG C of drying in oven, weighs.The weight claimed is deducted cotton balls weight and granuloma weight.Experimental result: in table 2
The impact that table 2 swells on rat granuloma
* * P < 0.01 compared with matched group; With ZHICHUANG GAO of the present invention than △ P < 0.05.
Result shows: ZHICHUANG GAO group of the present invention and b group, c group, d group cause the granuloma of rat to have obvious inhibitory action to cotton balls, have pole significant difference (P < 0.01) compared with matched group; ZHICHUANG GAO of the present invention has significant difference (P < 0.05) compared with b group, c group, d group.Visible, ZHICHUANG GAO of the present invention is stronger than b group, c group, the effect of d group anti-chronic inflammatory disease.
Three, on the impact of mouse peritoneal capillary permeability
Experiment material
1, animal: Kunming mouse, male and female have concurrently, body weight 18 ~ 22g.
2, medicine: ZHICHUANG GAO of the present invention and b group, c group, d group four dosage groups.
Experimental technique
Kunming mouse 50, male and female half and half, body weight 18 ~ 22g, is divided into 5 groups at random, often organizes 10.Matched group smears the vaseline of equivalent; ZHICHUANG GAO group of the present invention and b group, c group, d group are smeared administration respectively and are 2.4g/kg.Abdominal part depilation administration, successive administration 4d, every day 1 time, after last administration 1h, every mice presses azovan blue 0.9% sodium chloride solution of 5mL/kg body weight tail vein injection 0.5%, and after 5min, every mice presses the acetum of 10mL/kg body weight lumbar injection 0.7%.Put to death mice after 30min, open abdominal cavity, repeatedly rinse abdominal cavity to colourless with distilled water, it is 5mL that collection flushing liquor finally adds water to volume, adds the sodium hydroxide solution 0.1mL of 0.1mol/L, places 20min after mixing, centrifugal, get supernatant and survey absorption angle value at 610nm place.Experimental result: in table 3
Table 3 is on the impact of mouse peritoneal capillary permeability
* * P < 0.01 compared with matched group; With ZHICHUANG GAO of the present invention than △ P < 0.05.
Result shows: ZHICHUANG GAO group of the present invention and b group, c group, d group obviously suppress the permeability of mouse peritoneal blood capillary, have pole significant difference (P < 0.01) compared with matched group; ZHICHUANG GAO of the present invention has significant difference (P < 0.05) compared with b group, c group, d group.Visible, ZHICHUANG GAO of the present invention is stronger than b group, c group, the inhibitory action of d group to edema inflammatory seep.
Four, the impact of Dichlorodiphenyl Acetate induced mice writhing response
Experiment material
1, animal: Kunming mouse, male and female have concurrently, body weight 18 ~ 22g.
2, medicine: ZHICHUANG GAO of the present invention and b group, c group, d group four dosage groups.
Experimental technique
Kunming mouse 50, male and female half and half, body weight 18 ~ 22g, is divided into 5 groups at random, often organizes 10.Matched group smears the vaseline of equivalent; ZHICHUANG GAO group of the present invention and b group, c group, d group are smeared administration respectively and are 2.4g/kg.Abdominal part depilation administration, successive administration 4d, every day 1 time, after last administration 2h, every Mus equal lumbar injection 0.6% acetic acid 0.1ml/10g, there is abdominal part indent in mice, trunk and hind leg are upheld, the writhing responses such as hips up, mouse writhing number of times in record 15min.Experimental result: in table 4
The impact of table 4 Dichlorodiphenyl Acetate induced mice writhing response
* * P < 0.01 compared with matched group; With ZHICHUANG GAO of the present invention than △ P < 0.05.
Result shows: ZHICHUANG GAO group of the present invention and b group, c group, d group significantly can reduce mice is caused pain writhing number of times by glacial acetic acid, have pole significant difference (P < 0.01) compared with matched group; ZHICHUANG GAO of the present invention has significant difference (P < 0.05) compared with b group, c group, d group.Visible, ZHICHUANG GAO of the present invention is stronger than the analgesic activity of b group, c group, d group.
Five, on the impact of mouse hot-plate induced pain
Experiment material
1, animal: Kunming mouse, female, body weight 18 ~ 22g.
2, medicine: ZHICHUANG GAO of the present invention and b group, c group, d group four dosage groups.
Experimental technique
Electric hot plate instrument is adjusted to (55 ± 0.5) DEG C, the Kunming kind female mice that body weight is 18 ~ 22g is screened, record mice drops into hot plate to the pain threshold of time as this mice occurring licking metapedes, the female mice 50 of screening pain threshold in 30s, be divided into 5 groups at random, often organize 10.Matched group smears the vaseline of equivalent; ZHICHUANG GAO group of the present invention and b group, c group, d group are smeared administration respectively and are 2.4g/kg.Abdominal part depilation administration, successive administration 4d, every day 1 time, after last administration 2h, is placed in electric hot plate instrument by mice, after record administration, the time of licking metapedes appears in mice.Experimental result: in table 5
Table 5 is on the impact of mouse hot-plate induced pain
* * P < 0.01 compared with matched group; With ZHICHUANG GAO of the present invention than △ P < 0.05.
Result shows: ZHICHUANG GAO group of the present invention and b group, c group, d group can significantly improve the pain threshold of hot plate induced pain mice, has pole significant difference (P < 0.01) compared with matched group; ZHICHUANG GAO of the present invention has significant difference (P < 0.05) compared with b group, c group, d group.Visible, ZHICHUANG GAO of the present invention is stronger than b group, c group, d group analgesic activity.
Six, on the impact of clotting time of mice
Experiment material
1, animal: Kunming mouse, male and female have concurrently, body weight 18 ~ 22g.
2, medicine: ZHICHUANG GAO of the present invention and b group, c group, d group four dosage groups.
Experimental technique
Kunming mouse 50, male and female half and half, body weight 18 ~ 22g, is divided into 5 groups at random, often organizes 10.Matched group smears the vaseline of equivalent; ZHICHUANG GAO group of the present invention and b group, c group, d group are smeared administration respectively and are 2.4g/kg.Abdominal part depilation administration, successive administration 4d, every day 1 time, after last administration 1h, uses internal diameter 1mm, and the capillary glass tube of long 15cm inserts eyeball of mouse rear vein beard and gets blood, and put in glass capillary, thrombosis reaches 0.5cm.To fracture one section, capillary tube every 30s, checking with or without there is blood clotting silk, calculating from capillary glass blood sampling tube to the time occurring blood clotting silk, being clotting time.Experimental result: in table 6
Table 6 is on the impact of clotting time of mice
* * P < 0.01 compared with matched group; With ZHICHUANG GAO of the present invention than △ P < 0.05.
Result shows: ZHICHUANG GAO group of the present invention and b group, c group, d group obviously can shorten the clotting time of mice, have pole significant difference (P < 0.01) compared with matched group; ZHICHUANG GAO of the present invention has significant difference (P < 0.05) compared with b group, c group, d group.Visible, ZHICHUANG GAO of the present invention is stronger than b group, c group, d group Blood clotting.
Seven, the mice bleeding time is affected
Experiment material
1, animal: Kunming mouse, male and female have concurrently, body weight 18 ~ 22g.
2, medicine: ZHICHUANG GAO of the present invention and b group, c group, d group four dosage groups.
Experimental technique
Kunming mouse 50, male and female half and half, body weight 18 ~ 22g, is divided into 5 groups at random, often organizes 10.Matched group smears the vaseline of equivalent; ZHICHUANG GAO group of the present invention and b group, c group, d group are smeared administration respectively and are 2.4g/kg.Abdominal part depilation administration, successive administration 4d, every day 1 time, after last administration 1h, is positioned over mice in holder, is cutting off apart from tail point 2mm place, and 1.5cm depths under tail point being immersed 37 DEG C of normal saline liquid levels, the record bleeding time.Experimental result: in table 7
Table 7 is on the impact in mice bleeding time
* * P < 0.01 compared with matched group; With ZHICHUANG GAO of the present invention than △ P < 0.05.
Result shows: ZHICHUANG GAO group of the present invention and b group, c group, d group obviously shorten the bleeding time, has pole significant difference (P < 0.01) compared with matched group; ZHICHUANG GAO of the present invention has significant difference (P < 0.05) compared with b group, c group, d group.Visible, ZHICHUANG GAO of the present invention is better than b group, c group, d group haemostatic effect.
Experimental result: ZHICHUANG GAO group of the present invention and b group, c group, d group can significantly alleviate the swelling being caused Mice Auricle by dimethylbenzene; The granuloma of rat is caused to have obvious inhibitory action to cotton balls; The permeability of obvious suppression mouse peritoneal blood capillary; Significantly can reduce mice is caused pain writhing number of times by glacial acetic acid; Significantly improve the pain threshold of hot plate induced pain mice; Obviously can shorten the clotting time of mice; The obvious shortening bleeding time.
Conclusion: ZHICHUANG GAO of the present invention is stronger than the effect such as antiinflammatory, analgesia, blood coagulation, hemostasis of b group, c group, d group, therefore ZHICHUANG GAO of the present invention is than b group, c group, d group heat clearing and damp drying, promoting blood circulation and detumescence, and the effect of removing the necrotic tissue and promoting granulation is strong.
Toxicological experiment:
Acute toxicity testing result shows: the depilation of the abdominal part of ZHICHUANG GAO maximal dose of the present invention is smeared administration, successive administration 3 times in 24h, every minor tick 4h, and accumulation medicine total amount reaches 28g/kg, is equivalent to 280 times of clinical plan consumption.After administration in 7d, mice activity, feed, excretion are all normal, well-grown, and hair color light, its average body weight average increases with the prolongation of test period.8d place post mortem every the mice perusal heart, liver, spleen, lung, kidney, brain, thymus, uterus, stomach, intestinal etc. all do not find color and paramophia, fail to measure LD50.Show that ZHICHUANG GAO of the present invention is without acute toxic reaction.
Long term toxicity test result shows: ZHICHUANG GAO of the present invention is divided into basic, normal, high dosage to be respectively 4,8,16g/kg/d, be equivalent to 40,80,160 times of clinical dosage, abdominal part depilation smeared administration after 12 weeks, ZHICHUANG GAO of the present invention is on the general status of animal, hematological indices, blood parameters all without significantly impact, and Systematic anatomy, organ coefficient and histopathological examination be no abnormal pathological change also.Drug withdrawal also has no obvious change in 2 weeks.ZHICHUANG GAO of the present invention, in long term toxicity test, does not find overt toxicity reaction and delayed toxicity reaction.Visible, ZHICHUANG GAO non-toxic reaction of the present invention, long-term prescription is safe and reliable.
Detailed description of the invention
1, the preparation of ointment of the present invention:
Formula:
Preparation method:
A, Margarita, succinum to be pulverized, cross 100-120 mesh sieve;
B, by artificial Moschus, artificial Calculus Bovis, Borax, Borneolum Syntheticum, 1/5 Calamina (calcined and quenched) and steps A gained Margarita powder, Succinum powder facing-up, cross 100-120 mesh sieve;
C, step B gained medicated powder to be mixed homogeneously with 4/5 Calamina (calcined and quenched);
D, mixed medicated powder to be pulverized by drug powder metallization processes, obtain former powder;
E, by vaseline temperature control 80-100 DEG C fusing after, temperature control 115-120 DEG C sterilizing, is cooled to 70-80 DEG C by sterilized vaseline;
F, by lanoline in temperature control 115-120 DEG C sterilizing;
G, by dimethyl sulfoxine temperature control 55-65 DEG C to fusing;
H, first vaseline is put into material-compound tank, put into a half and stir; Secondly by Borneolum Syntheticum, dimethyl sulfoxine and lanoline congruent melting, filter and drop in material-compound tank and stir; 3rd is that former for step D gained powder is added material-compound tank, and stir, fill, obtains ointment.
2, the preparation of ointment of the present invention:
Formula:
Preparation method:
A, Margarita, succinum to be pulverized, cross 100-120 mesh sieve;
B, by artificial Moschus, artificial Calculus Bovis, Borax, Borneolum Syntheticum, 1/5 Calamina (calcined and quenched) and steps A gained Margarita powder, Succinum powder facing-up, cross 100-120 mesh sieve;
C, step B gained medicated powder to be mixed homogeneously with 4/5 Calamina (calcined and quenched);
D, mixed medicated powder to be pulverized by drug powder metallization processes, obtain former powder;
E, by vaseline temperature control 80-100 DEG C fusing after, temperature control 115-120 DEG C sterilizing, is cooled to 70-80 DEG C by sterilized vaseline;
F, by lanoline in temperature control 115-120 DEG C sterilizing;
G, by dimethyl sulfoxine temperature control 55-65 DEG C to fusing;
H, first vaseline is put into material-compound tank, put into a half and stir; Secondly by Borneolum Syntheticum, dimethyl sulfoxine and lanoline congruent melting, filter and drop in material-compound tank and stir; 3rd is that former for step D gained powder is added material-compound tank, and stir, fill, obtains ointment.
3, the preparation of ointment of the present invention:
Formula;
Preparation method:
A, Margarita, succinum to be pulverized, cross 100-120 mesh sieve;
B, by artificial Moschus, artificial Calculus Bovis, Borax, Borneolum Syntheticum, 1/5 Calamina (calcined and quenched) and steps A gained Margarita powder, Succinum powder facing-up, cross 100-120 mesh sieve;
C, step B gained medicated powder to be mixed homogeneously with 4/5 Calamina (calcined and quenched);
D, mixed medicated powder to be pulverized by drug powder metallization processes, obtain former powder;
E, by vaseline temperature control 80-100 DEG C fusing after, temperature control 115-120 DEG C sterilizing, is cooled to 70-80 DEG C by sterilized vaseline;
F, by lanoline in temperature control 115-120 DEG C sterilizing;
G, by dimethyl sulfoxine temperature control 55-65 DEG C to fusing;
H, first vaseline is put into material-compound tank, put into a half and stir; Secondly by Borneolum Syntheticum, dimethyl sulfoxine and lanoline congruent melting, filter and drop in material-compound tank and stir; 3rd is that former for step D gained powder is added material-compound tank, and stir, fill, obtains ointment.
4, the preparation of ointment of the present invention:
Formula:
Preparation method:
A, Margarita, succinum to be pulverized, cross 100-120 mesh sieve;
B, by artificial Moschus, artificial Calculus Bovis, Borax, Borneolum Syntheticum, 1/5 Calamina (calcined and quenched) and steps A gained Margarita powder, Succinum powder facing-up, cross 100-120 mesh sieve;
C, step B gained medicated powder to be mixed homogeneously with 4/5 Calamina (calcined and quenched);
D, mixed medicated powder to be pulverized by drug powder metallization processes, obtain former powder;
E, by vaseline temperature control 80-100 DEG C fusing after, temperature control 115-120 DEG C sterilizing, is cooled to 70-80 DEG C by sterilized vaseline;
F, by lanoline in temperature control 115-120 DEG C sterilizing;
G, by dimethyl sulfoxine temperature control 55-65 DEG C to fusing;
H, first vaseline is put into material-compound tank, put into a half and stir; Secondly by Borneolum Syntheticum, dimethyl sulfoxine and lanoline congruent melting, filter and drop in material-compound tank and stir; 3rd is that former for step D gained powder is added material-compound tank, and stir, fill, obtains ointment.
Claims (1)
1. treat an ointment for hemorrhoid class anorectal, it is characterized in that the formula of described ointment consists of:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310348794.6A CN103393724B (en) | 2013-08-13 | 2013-08-13 | Ointment for treating perianal abscess and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310348794.6A CN103393724B (en) | 2013-08-13 | 2013-08-13 | Ointment for treating perianal abscess and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103393724A CN103393724A (en) | 2013-11-20 |
| CN103393724B true CN103393724B (en) | 2015-05-20 |
Family
ID=49557579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310348794.6A Expired - Fee Related CN103393724B (en) | 2013-08-13 | 2013-08-13 | Ointment for treating perianal abscess and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103393724B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103933196B (en) * | 2014-03-14 | 2016-01-20 | 唐淑云 | A kind of Chinese medicine fuming-lotion for the treatment of hemorrhoid |
| CN108653356A (en) * | 2018-05-30 | 2018-10-16 | 安徽德睿轩科技服务有限公司 | A kind of pharmaceutical composition and its application for treating anorectal disease |
| CN110302342B (en) * | 2019-08-15 | 2021-06-01 | 刘振武 | Ointment for treating hemorrhoids and preparation method thereof |
| CN113521166B (en) * | 2020-12-02 | 2022-05-03 | 马应龙药业集团股份有限公司 | A cream for treating anorectal diseases such as hemorrhoid, and its preparation method |
| CN114652750B (en) * | 2022-03-08 | 2023-05-26 | 马应龙药业集团股份有限公司 | Application of traditional Chinese medicine composition in preparation of colorectal cancer prevention medicines |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1362151A (en) * | 2001-01-02 | 2002-08-07 | 杨孟君 | Nano Mayinglong pile-treating musk medicine and its preparation |
| CN1403098A (en) * | 2002-10-18 | 2003-03-19 | 武汉马应龙药业集团股份有限公司 | Ointment for treating piles and other anorectal diseases and its prepn |
| CN1403097A (en) * | 2002-10-18 | 2003-03-19 | 武汉马应龙药业集团股份有限公司 | Sore ulcer treating ointment and its prepn |
| CN1903289A (en) * | 2006-08-08 | 2007-01-31 | 武汉马应龙药业集团股份有限公司 | Gel for treating hemorrhoidal anus and rectum diseases, and its prepn. method |
-
2013
- 2013-08-13 CN CN201310348794.6A patent/CN103393724B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1362151A (en) * | 2001-01-02 | 2002-08-07 | 杨孟君 | Nano Mayinglong pile-treating musk medicine and its preparation |
| CN1403098A (en) * | 2002-10-18 | 2003-03-19 | 武汉马应龙药业集团股份有限公司 | Ointment for treating piles and other anorectal diseases and its prepn |
| CN1403097A (en) * | 2002-10-18 | 2003-03-19 | 武汉马应龙药业集团股份有限公司 | Sore ulcer treating ointment and its prepn |
| CN1903289A (en) * | 2006-08-08 | 2007-01-31 | 武汉马应龙药业集团股份有限公司 | Gel for treating hemorrhoidal anus and rectum diseases, and its prepn. method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103393724A (en) | 2013-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103393724B (en) | Ointment for treating perianal abscess and preparation method thereof | |
| CN101455745A (en) | Medicine composition for treating hemorrhoids and preparation method thereof | |
| CN104288167B (en) | It is a kind of to treat otoginsenoside preparation of sodium of hemorrhoid and preparation method thereof | |
| CN101628045B (en) | Medicine for treating piles and its preparing process | |
| CN101890100B (en) | Medicament for curing dermatitis and eczema and preparation method thereof | |
| CN103251765B (en) | Traditional Chinese medicine composition for treating lumbar intervertebral disc herniation and preparation method thereof | |
| CN104116791B (en) | A kind of external miticide compositions and its production and use | |
| CN103271983B (en) | A kind of endometritis and colpitic perfusion liquid, its preparation method and application for the treatment of pig | |
| CN102727794B (en) | Traditional Chinese medical prescription for treating burn and scald, traumatic injury and rheumatism bone pain | |
| CN101797289A (en) | Oral spraying agent prepared from traditional Chinese medicine and preparation method thereof | |
| CN102579899B (en) | Preparation method of traditional Chinese medical composition for spur pain elimination | |
| CN105326955A (en) | Composition for treating blepharitis and preparing method thereof | |
| CN104840581A (en) | Traditional veterinary medicine combination for treating prolonged lochia and delayed estrus of sow and preparation method thereof | |
| CN1943701B (en) | A kind of medicine for treatment of non-gonococcal urethritis(NGU) and its preparation method | |
| CN104474045A (en) | Traditional Chinese medicine patch for treating febrile convulsion of infants and preparation method of traditional Chinese medicine patch | |
| CN109925426A (en) | A kind of herbal fumigation agent can treat hemorrhoid | |
| CN106880683A (en) | External-applied ointment for treating hemorrhoid | |
| CN108030814A (en) | A kind of Chinese medicinal preparation method for the mucus or purulent inflammation that can treat cow uteri mucous membrane | |
| CN102614375B (en) | Traditional Chinese medicine compound for tonifying kidney, strengthening yang and treating impotence and preparing method thereof | |
| CN101485847B (en) | Chinese medicinal composition for treating prostatic diseases and preparation method thereof | |
| CN100408085C (en) | Snow lotus preparation for treating prostate disease | |
| CN105963338B (en) | Prevent and treat the herbal composite of cervical erosion | |
| CN105106431A (en) | Traditional Chinese medicine perfusion agent for treating cow ovarian quiescence and persistent corpus luteum infertility and preparation method thereof | |
| CN105726713B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| Kulvajtová et al. | Issues of electric shock in forensic medical practice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150520 Termination date: 20180813 |